ImpediMed Limited (IPD.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
At close: 04:10PM AEDT
Loading interactive chart…
- Simply Wall St.
ImpediMed First Half 2023 Earnings: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)
ImpediMed ( ASX:IPD ) First Half 2023 Results Key Financial Results Revenue: AU$5.66m (up 8.8% from 1H 2022). Net loss...
- Simply Wall St.
Will ImpediMed (ASX:IPD) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- PR Newswire
New Data Presented at the 2022 San Antonio Breast Cancer Symposium Shows Early Detection using L-Dex and Intervention Improves Lymphedema Progression-Free Survival
ImpediMed Limited (ASX: IPD) is pleased to announce a poster showing that breast cancer patients receiving early detection of lymphedema using ImpediMed's L-Dex® technology and intervention had statistically higher rates of lymphedema progression-free survival through three years compared to using tape measure was presented at the 2022 San Antonio Breast Cancer Symposium on December 6-10, 2022 in San Antonio, Texas.
© 2023 Yahoo. All rights reserved.
